Esperion Therapeutics (ESPR) Down 15.1% Since Last Earnings Report: Can It Rebound?
nasdaq.com
news
2022-06-02 11:31:00

A month has gone by since the last earnings report for Esperion Therapeutics (ESPR). Shares have lost about 15.1% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Esperion Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

Esperion Q1 Earnings & Revenues Top Estimates

Esperion incurred a loss per share of 93 cents per share for the first quarter of 2022, narrower than the Zacks Consensus Estimate of a loss of 96 cents per share.
